United States - English - NLM (National Library of Medicine)

piramal critical care inc - sevoflurane (unii: 38lvp0k73a) (sevoflurane - unii:38lvp0k73a) - sevoflurane 1 ml in 1 ml - sojourn ® (sevoflurane, usp) is indicated for induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery. sojourn ® (sevoflurane, usp) should be administered only by persons trained in the administration of general anesthesia. facilities for maintenance of a patent airway, artificial ventilation, oxygen enrichment, and circulatory resuscitation must be immediately available. since level of anesthesia may be altered rapidly, only vaporizers producing predictable concentrations of sevoflurane, usp should be used. • known or suspected genetic susceptibility to malignant hyperthermia. (see warnings - malignant hyperthermia,clinical pharmacology - pharmacogenomics ). • known or suspected sensitivity to sevoflurane or to other halogenated inhalational anesthetics.

United States - English - NLM (National Library of Medicine)

piramal critical care inc - sevoflurane (unii: 38lvp0k73a) (sevoflurane - unii:38lvp0k73a) - sevoflurane 1 ml in 1 ml - sevoflurane, usp is indicated for induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery. sevoflurane, usp should be administered only by persons trained in the administration of general anesthesia. facilities for maintenance of a patent airway, artificial ventilation, oxygen enrichment, and circulatory resuscitation must be immediately available. since level of anesthesia may be altered rapidly, only vaporizers producing predictable concentrations of sevoflurane, usp should be used. • known or suspected genetic susceptibility to malignant hyperthermia. (see warnings - malignant hyperthermia, clinical pharmacology - pharmacogenomics ). • known or suspected sensitivity to sevoflurane or to other halogenated inhalational anesthetics.

United States - English - NLM (National Library of Medicine)

piramal critical care inc - sevoflurane (unii: 38lvp0k73a) (sevoflurane - unii:38lvp0k73a) - sevoflurane, usp is indicated for induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery. sevoflurane, usp should be administered only by persons trained in the administration of general anesthesia. facilities for maintenance of a patent airway, artificial ventilation, oxygen enrichment, and circulatory resuscitation must be immediately available. since level of anesthesia may be altered rapidly, only vaporizers producing predictable concentrations of sevoflurane should be used. • known or suspected genetic susceptibility to malignant hyperthermia. (see warnings-malignant hyperthermia,clinical pharmacology - pharmacogenomics). • known or suspected sensitivity to sevoflurane or to other halogenated inhalational anesthetics.

Australia - English - Department of Health (Therapeutic Goods Administration)

piramal critical care pty ltd - alfentanil hydrochloride, quantity: 0.544 mg/ml - injection, solution - excipient ingredients: water for injections; sodium chloride - indications: rapifen is indicated for intravenous use by specialist anaesthetists and their trainees as 1. an analgesic supplement given by incremental intravenous boluses or continuous infusion; and 2. an anaesthetic induction agent where in patients undergoing in-patient surgery, when endotracheal intubation and controlled ventilation are to be used. because of its rapid onset and short duration of action, intravenous rapifen is particularly suited as a narcotic analgesic for short procedures and outpatients, provided that the patients are maintained under appropriate post-operative surveillance. however, intravenous rapifen is also useful as an analgesic supplement for procedures of medium to long duration, since periods of very painful stimuli can be easily overcome by administration of small increments of rapifen or by adapting the infusion rate.

Australia - English - Department of Health (Therapeutic Goods Administration)

piramal critical care pty ltd - alfentanil hydrochloride, quantity: 0.544 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections - indications: rapifen is indicated for intravenous use by specialist anaesthetists and their trainees as 1. an analgesic supplement given by incremental intravenous boluses or continuous infusion; and 2. an anaesthetic induction agent where in patients undergoing in-patient surgery, when endotracheal intubation and controlled ventilation are to be used. because of its rapid onset and short duration of action, intravenous rapifen is particularly suited as a narcotic analgesic for short procedures and outpatients, provided that the patients are maintained under appropriate post-operative surveillance. however, intravenous rapifen is also useful as an analgesic supplement for procedures of medium to long duration, since periods of very painful stimuli can be easily overcome by administration of small increments of rapifen or by adapting the infusion rate.

Zimbabwe - English - Medicines Control Authority

piramal critical care, inc - sevoflurane - inhalation - 100 %

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

piramal critical care, inc. - isoflurano - isoflurano....100%

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

piramal critical care, inc. - sevoflurano - sevoflurano....1.00 ml

Canada - English - Health Canada

piramal critical care inc - sevoflurane - liquid - 99.97% - sevoflurane 99.97% - inhalation anesthetics

United States - English - NLM (National Library of Medicine)

piramal critical care inc - baclofen (unii: h789n3fke8) (baclofen - unii:h789n3fke8) - baclofen 50 ug in 1 ml - gablofen is indicated for use in the management of severe spasticity in adult and pediatric patients age 4 years and above. patients should first respond to a screening dose of intrathecal baclofen prior to consideration for long term infusion via an implantable pump. for spasticity of spinal cord origin, chronic infusion of gablofen via an implantable pump should be reserved for patients unresponsive to oral baclofen therapy, or those who experience intolerable cns side effects at effective doses. patients with spasticity due to traumatic brain injury should wait at least one year after the injury before consideration of long term intrathecal baclofen therapy. gablofen is intended for use by the intrathecal route in single bolus test doses (via spinal catheter or lumbar puncture) and, for chronic use, only with the medtronic synchromed ® ii programmable pump or other pumps labeled for intrathecal administration of gablofen [see clinical studies (14)] . prior to implantation of